Comparative Pharmacology
Head-to-head clinical analysis: FABIOR versus SORIATANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FABIOR versus SORIATANE.
FABIOR vs SORIATANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), inducing differentiation and apoptosis of keratinocytes.
Retinoid that binds to nuclear retinoic acid receptors (RARs), modulating gene expression involved in cell proliferation, differentiation, and apoptosis.
FABIOR (tazarotene) foam, 0.1%: Apply a thin layer once daily in the evening to affected areas of the face, scalp, or trunk.
Initial: 25-50 mg orally once daily; maintenance: 25-50 mg orally once daily; not to exceed 75 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 24-26 hours, supporting once-daily dosing.
Terminal elimination half-life of etretinate (active form) is ≈100–125 days due to storage in adipose tissue; clinically relevant for prolonged teratogenicity.
Primarily hepatic metabolism via CYP450; renal excretion of metabolites accounts for <1% of dose as unchanged drug. Fecal elimination is the major route (approximately 90%).
Primarily hepatic metabolism; eliminated via feces (≈60%) and urine (≈15%) as metabolites; parent drug not excreted unchanged.
Category C
Category C
Retinoid
Retinoid